Urogen Pharma LTD

UroGen Pharma Ltd. announced a settlement and license agreement with Teva Pharmaceuticals to resolve patent litigation concerning Jelmyto, granting Teva a license for its generic version starting September 15, 2030.

UroGen Pharma reported strong Q1 2026 financial results, driven by a more than doubling of ZUSDURI revenue quarter-over-quarter, alongside steady growth for JELMYTO and pipeline advancements.

UroGen Pharma announced its Q4 and full-year 2025 financial results, highlighting the successful launch of ZUSDURI and robust JELMYTO sales.

UroGen Pharma Ltd. secured a new $250 million term loan facility, with $200 million immediately funded to refinance existing debt and support general corporate needs.

UroGen Pharma reported its Q3 2025 financial results, highlighting accelerating ZUSDURI launch momentum and solid JELMYTO revenue growth, alongside pipeline updates and a strategic discontinuation.

UroGen Pharma Ltd. shareholders approved an amended compensation policy and an increase of 2.75 million shares to its equity incentive plan at the 2025 Annual Meeting.

Urogen Pharma Ltd. announced a Second Amended and Restated Loan Agreement, increasing its credit facility to $250 million with BioPharma Credit PLC.

UroGen Pharma reports Q3 2025 results, highlighting the commercial launch of Zusduri, progress in its RTGel pipeline, and a significant lease extension for its Princeton headquarters, alongside increased operating losses.

UroGen Pharma reported increased revenue from Jelmyto sales but wider net losses in Q2 2025, alongside the significant FDA approval of Zusduri and progress in its pipeline.

UroGen Pharma announces its financial results for the first quarter of 2025, highlighting revenue growth and continued progress towards the PDUFA date for UGN-102.

UroGen Pharma's Q3 2024 results show increased revenue and progress in clinical trials, particularly for UGN-102, while also highlighting ongoing losses and strategic financial activities.

UroGen Pharma's second quarter 2024 results show increased revenue and ongoing clinical development of key product candidates.

UroGen Pharma's 2025 annual report details significant revenue growth driven by Jelmyto and Zusduri sales, alongside pipeline advancements and increased operating losses.

UroGen Pharma files an amendment to its 2024 annual report to include information required by Part III of Form 10-K, covering directors, executive officers, compensation, security ownership, related transactions, and accountant fees.

UroGen Pharma details its financial performance for 2024 and provides updates on its key product pipeline, including the FDA's acceptance of the NDA for UGN-102.

UroGen Pharma has filed an amendment to its 2023 annual report to include information required by Part III of Form 10-K, specifically detailing director and executive information, compensation, and governance.

UroGen Pharma Ltd. amends its manufacturing and supply agreement with Cenexi-Laboratoires Thissen S.A. to prepare for increased production volumes and files its annual 10-K report, detailing financial results and pipeline advancements.

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, has sold 10,000 ordinary shares for approximately $400,000 as part of a pre-arranged trading plan.

UroGen Pharma Ltd. reports a significant stock transaction by Chief Medical Officer Mark Schoenberg, who sold 10,000 ordinary shares valued at approximately $350,100 under a pre-arranged trading plan.

UroGen Pharma Ltd. director Daniel George Wildman acquired 10,000 stock options and 8,000 Restricted Stock Units, indicating a significant equity grant.

UroGen Pharma director James A. Robinson Jr. reported the acquisition of stock options and restricted stock units, indicating a vested interest in the company's future.

UroGen Pharma Ltd. director Stuart Holden was granted 20,000 stock options with an exercise price of $34.99, vesting over one year.

Cynthia M. Butitta, a Director at UroGen Pharma Ltd., acquired 10,000 stock options and 8,000 Restricted Stock Units (RSUs) on June 22, 2026.

UroGen Pharma has filed its definitive proxy statement for the 2026 Annual Meeting of Shareholders to be held on June 22, 2026.

UroGen Pharma Ltd. is convening its 2025 Annual Meeting to vote on key proposals including the election of directors, significant increases in equity compensation for officers and directors, and an expansion of its equity incentive plan, following recent FDA approval for Zusduri and growth in Jelmyto revenue.

Urogen Pharma Ltd. has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.

UroGen Pharma has released its proxy statement detailing proposals for its upcoming 2024 Annual Meeting of Shareholders, including director elections, compensation policies, and equity incentive plan amendments.

Monograph Capital Partners I, L.P. and its affiliated reporting persons have filed an exit amendment to their Schedule 13D, indicating they no longer beneficially own more than 5% of UroGen Pharma Ltd.'s Ordinary Shares after selling 733,712 shares.

Paradigm BioCapital Advisors and associated entities have filed a Schedule 13G reporting a 3.5% beneficial ownership stake in UroGen Pharma Ltd.

The Toronto-Dominion Bank and TD Securities Inc. have filed a Schedule 13G, reporting beneficial ownership of 5.4% of UroGen Pharma Ltd.'s ordinary shares as of March 31, 2026.

BlackRock, Inc. has reported beneficial ownership of 5.2% of Urogen Pharma Ltd's common stock as of March 31, 2026.

The Toronto-Dominion Bank has reported a 4.9% beneficial ownership stake in UroGen Pharma Ltd., holding over 2.3 million ordinary shares.

Paradigm BioCapital Advisors LP and related entities have disclosed a 9.0% beneficial ownership stake in UroGen Pharma Ltd. as of September 30, 2025.

The Toronto-Dominion Bank has reported a 6.9% beneficial ownership stake in UroGen Pharma Ltd., holding 3,190,510 ordinary shares.